Pharmaceuticals company Senores Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total income of Rs 120 crore has been achieved in Q4FY25 compared to Rs 102 crore in Q4FY24 EBITDA of Rs 25.4 crore has been achieved in Q4FY25 compared to Rs 22.4 crore in Q4FY24 PBT of Rs 20.7 crore has been achieved in Q4FY25 compared to Rs 17.6 crore in Q4FY24 FY25 Financial Highlights: Total income of Rs 410 crore has been achieved in FY25 vs Rs 214 crore in FY24 EBITDA of Rs 101.8 crore has been achieved in FY25 vs Rs 41.6 crore in FY24 PBT of Rs 70.6 crore has been achieved in FY25 vs Rs 24.9 crore in FY24 Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals said, “We are pleased to report strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our Total Income and Profit before Tax for FY25 have increased by 91% & 183% respectively on year-on-year basis, and we are optimistic about sustaining this momentum going forward. We continued to make steady progress on our stated strategies. During the quarter, we expanded our portfolio in the Regulated Markets through acquisition of 14 ANDA’s from Dr. Reddy’s and 1 ANDA from Breckenridge Pharmaceuticals. A large part of this acquired ANDA basket has considerable government contract opportunities. Further, our CDMO/CMO segment is gaining traction and continued to scale up well. We have launched 1 new product in the CDMO/CMO segment during the quarter and have 69 products in pipeline. Our shift in product portfolio and go-to-market strategies in the Emerging Markets business is beginning to give the desired results, which can be seen in the improvement in margin during the quarter. We have registered 48 new products across the Emerging Markets during Q4FY25, taking the total portfolio to 285 registered products. Going forward, although the uncertainties due to the tariff situation in USA will have to be closely monitored, we believe we are well placed to navigate the same, given our USFDA-approved manufacturing facility in USA. We will continue to focus on three key pillars going forward – Expansion of ANDA portfolio in Regulated Markets; Steady scale-up of CDMO/CMO segment in the Regulated Markets; and Portfolio expansion and profitability improvement in the Emerging Markets.” Result PDF